## David V Hansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2241020/publications.pdf Version: 2024-02-01



DAVID V HANSEN

#	Article	IF	CITATIONS
1	Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Neuron, 2021, 109, 1283-1301.e6.	8.1	137
2	TREM2-independent oligodendrocyte, astrocyte, and TÂcell responses to tau and amyloid pathology in mouse models of Alzheimer disease. Cell Reports, 2021, 37, 110158.	6.4	33
3	Genome-Wide Analysis of Differential Gene Expression and Splicing in Excitatory Neurons and Interneuron Subtypes. Journal of Neuroscience, 2020, 40, 958-973.	3.6	51
4	Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. Cell Reports, 2020, 31, 107843.	6.4	222
5	Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. Journal of Neuroscience, 2020, 40, 1956-1974.	3.6	114
6	Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Reports, 2019, 28, 2111-2123.e6.	6.4	271
7	Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. Cell Reports, 2018, 22, 832-847.	6.4	499
8	Microglia in Alzheimer's disease. Journal of Cell Biology, 2018, 217, 459-472.	5.2	1,188
9	Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease. PLoS Genetics, 2018, 14, e1007427.	3.5	56
10	A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. Journal of Alzheimer's Disease, 2017, 56, 1037-1054.	2.6	44
11	TREM2, Microglia, and Neurodegenerative Diseases. Trends in Molecular Medicine, 2017, 23, 512-533.	6.7	327
12	Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. Journal of Experimental Medicine, 2017, 214, 2611-2628.	8.5	101
13	Interfering with the Chronic Immune Response Rescues Chronic Degeneration After Traumatic Brain Injury. Journal of Neuroscience, 2016, 36, 9962-9975.	3.6	79
14	Antibody-Mediated Targeting of Tau InÂVivo Does Not Require Effector Function and Microglial Engagement. Cell Reports, 2016, 16, 1690-1700.	6.4	102
15	Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. Nature Communications, 2016, 7, 11295.	12.8	310
16	A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nature Medicine, 2014, 20, 1452-1457.	30.7	116
17	Non-epithelial stem cells and cortical interneuron production in the human ganglionic eminences. Nature Neuroscience, 2013, 16, 1576-1587.	14.8	253
18	A High-Resolution Enhancer Atlas of the Developing Telencephalon. Cell, 2013, 152, 895-908.	28.9	241

DAVID V HANSEN

#	Article	IF	CITATIONS
19	Mitotic spindle orientation predicts outer radial glial cell generation in human neocortex. Nature Communications, 2013, 4, 1665.	12.8	186
20	Development and Evolution of the Human Neocortex. Cell, 2011, 146, 18-36.	28.9	1,110
21	Deriving Excitatory Neurons of the Neocortex from Pluripotent Stem Cells. Neuron, 2011, 70, 645-660.	8.1	104
22	Neurogenic radial glia in the outer subventricular zone of human neocortex. Nature, 2010, 464, 554-561.	27.8	1,150
23	Cdc2 and Mos Regulate Emi2 Stability to Promote the Meiosis I–Meiosis II Transition. Molecular Biology of the Cell, 2008, 19, 3536-3543.	2.1	35
24	Emi2 at the Crossroads: Where CSF Meets MPF. Cell Cycle, 2007, 6, 732-738.	2.6	13
25	Translational Unmasking of Emi2 Directs Cytostatic Factor Arrest in Meiosis II. Cell Cycle, 2007, 6, 725-731.	2.6	26
26	Control of Emi2 activity and stability through Mos-mediated recruitment of PP2A. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16564-16569.	7.1	48
27	The Evi5 Oncogene Regulates Cyclin Accumulation by Stabilizing the Anaphase-Promoting Complex Inhibitor Emi1. Cell, 2006, 124, 367-380.	28.9	96
28	Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes and Development, 2006, 20, 2410-2420.	5.9	180
29	CaMKII and Polo-like kinase 1 sequentially phosphorylate the cytostatic factor Emi2/XErp1 to trigger its destruction and meiotic exit. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 608-613.	7.1	119
30	Mouse Emi2 is required to enter meiosis II by reestablishing cyclin B1 during interkinesis. Journal of Cell Biology, 2006, 174, 791-801.	5.2	163
31	A role for the anaphase-promoting complex inhibitor Emi2/XErp1, a homolog of early mitotic inhibitor 1, in cytostatic factor arrest of Xenopus eggs. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4318-4323.	7.1	151
32	Plk1 Regulates Activation of the Anaphase Promoting Complex by Phosphorylating and Triggering SCF <sup>βTrCP</sup> -dependent Destruction of the APC Inhibitor Emi1. Molecular Biology of the Cell, 2004, 15, 5623-5634.	2.1	191
33	Phylogenetic Analysis of Hoxa 11 Sequences Reveals Absence of Transposable Elements, Conservation of Transcription Factor Binding Sites, and Suggests Antisense Coding Function. DNA Sequence, 2002, 13, 77-83.	0.7	3
34	Control of the centriole and centrosome cycles by ubiquitination enzymes. Oncogene, 2002, 21, 6209-6221.	5.9	17
35	Selenium Regulates Expression in Rat Liver of Genes for Proteins Involved in Iron Metabolism. Biological Trace Element Research, 2000, 74, 55-70.	3.5	18